HEPATHROMBIN, Blunt trauma, superficial phlebitis 60,000 Gel
Hepathrombin®-Gel 60000
Active Blunt trauma, superficial phlebitis, HEPATHROMBIN Gel ingredient:
Heparin-Na from pig intestinal mucosa
Application Blunt trauma, superficial phlebitis, HEPATHROMBIN Gel:
For supportive treatment of acute swelling conditions after blunt trauma. Superficial phlebitis, if this cannot be treated by compression.
Notes:
Do not apply gel to mucous membranes or open wounds.
For supportive treatment of acute swelling conditions.
Active Blunt trauma, superficial phlebitis, HEPATHROMBIN Gel ingredients
- 600 IU pork heparin sodium
ingredients
- Isopropanol
- Disodium edetate-2-water
- Allantoin
- Poly(oxyethylene)-6-glycerol(mono/di)alkanoate (C8-C10)
- Dexpanthenol
- Carbomer 980
- Water, purified
- lemon oil
- Levomenthol
- Polysorbate 80
- Sorbitol 70
- Trometamol
- Pine needle oil
Indication :
- For supportive treatment of acute swelling following blunt injuries (bruises/bruises) and superficial phlebitis, provided this cannot be treated with compression.
Dosage :
- Always use this medicine exactly as described or exactly as discussed with your doctor or pharmacist. Check with your doctor or pharmacist if you are unsure.
-
The recommended dose is:
- Apply thinly and evenly to the affected area 2 - 3 times a day.
-
Duration of application
- The medicine must not be used for longer than 10 days.
-
If you have used more than you should
- Please contact your doctor or pharmacist if you have used more than you should.
-
If you forget to use it
- Do not use a double dose if you forget the previous dose.
-
If you cancel the application
- If you have any further questions about using this medicine, talk to your doctor or pharmacist. If you want to interrupt the treatment or end it prematurely, please consult your doctor or pharmacist first.
Way :
- Apply thinly and evenly to the affected area
Side effects :
- Like all medicines, this medicine can cause side effects, although not everyone gets them.
-
The frequency information on side effects is based on the following categories:
- Very common: more than 1 patient in 10
- Common: 1 to 10 treated in 100
- Uncommon: 1 to 10 people treated in 1,000
- Rare: 1 to 10 people treated in 10,000
- Very rare: less than 1 person treated in 10,000
- Not known: Frequency cannot be estimated from the available data
-
Possible side effects:
- Allergic reactions to heparin when applied to the skin are very rare. However, in individual cases, allergic reactions such as reddening of the skin and itching can occur, which usually disappear quickly after discontinuing the preparation.
-
Blood and hematopoietic system
- Not known: The frequency of occurrence of heparin-induced, antibody-mediated thrombocytopenia type II (reduction in the number of blood platelets < 100,000/µl or a rapid drop in the number of platelets to < 50% of the initial value), with arterial and venous thrombosis or embolism The potential for death has not yet been investigated when applied locally to the skin. However, since the absorption of heparin through healthy skin after local application has been described, this risk cannot be ruled out with certainty. Increased attention is therefore indicated.
- In patients without pre-existing hypersensitivity to heparin, the decrease in blood platelet counts usually begins 6 - 14 days after the start of treatment. In patients with hypersensitivity to heparin, this decrease may occur within hours.
-
What countermeasures should be taken in the event of side effects?
- The medicine should be discontinued if allergic skin reactions occur. Please inform your doctor about this. Beyond that, no other special measures are necessary.
- If you notice any side effects, contact your doctor or pharmacist. This also applies to side effects that are not specified.
Interactions :
-
When used together with other medicines
- Tell your doctor or pharmacist if you are taking/using any other medicines, have recently taken/used any other medicines or might take/use any other medicines.
- Interactions with other drugs are not known when used locally, but cannot be ruled out, especially with long-term use, as penetration of heparin through healthy skin has been described.
- Especially with drugs that interfere with blood clotting, such as platelet aggregation inhibitors (acetylsalicylic acid, ticlopidine, clopidogrel, dipyridamole in high doses), fibrinolytics, other anticoagulants (coumarin derivatives), non-steroidal anti-inflammatory drugs (phenylbutazone, indomethacin, sulfinpyrazone), glycoprotein IIb /IIa receptor antagonists, penicillin in high doses, dextrans, an increased risk of bleeding cannot be ruled out. Hematomas can occur more frequently or become more severe.
Contraindications :
-
The medicine must not be used
- if you are allergic to heparin or any of the other ingredients.
- if you have an acute or a history of allergic fall in the number of blood platelets (thrombocytopenia type II) caused by heparin.
Pregnancy and breastfeeding :
- Previous experience with use in pregnant and breastfeeding women has shown no evidence of harmful effects.
- Heparin does not cross the placenta and does not pass into breast milk.
- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Patient information :
-
Particular care is required when using it
-
If new symptoms appear that may indicate a thrombosis or pulmonary embolism, such as
- Swelling and feeling of warmth in the affected part of the body,
- red and tense skin, possibly blue discoloration,
- Feeling of tension and pain in the foot, calf and back of the knee (relief when elevated)
- Sudden shortness of breath, chest pain and weakness/collapse
- The presence of heparin-induced thombocytopenia type II must be ruled out and the blood platelet count (thrombocyte count) must be checked immediately.
- Regular checks of platelet levels are required every time heparin is used.
-
The platelet count should be checked:
- before starting heparin administration
- on the 1st day after the start of heparin administration
- then every 3 - 4 days until the end of heparin treatment
- If drugs that interfere with blood clotting are used at the same time, an increased risk of bleeding cannot be ruled out. Bruising may occur more frequently or increase in extent.
- During treatment, injections into the muscle should be avoided due to the risk of bruising (hematomas).
- The medicine should not be applied to open wounds and/or weeping eczema.
- The medicine contains alcohol and should therefore not come into contact with the eyes or mucous membranes.
-
Children and young people
-
Due to the lack of data on safety and effectiveness, the preparation is not
recommended for use in children and adolescents under 18 years of age.
-
Due to the lack of data on safety and effectiveness, the preparation is not
-
If new symptoms appear that may indicate a thrombosis or pulmonary embolism, such as
-
Ability to drive and use machines
- No restriction.